Concepedia

Tom Van den Mooter

TV

3

Publications

154

Citations

3

H-Index

2017

Active since

Affiliations

Cliniques Universitaires Saint-Luc(Current)

Centre Georges François Leclerc

GZA Ziekenhuizen Campus Sint-Augustinus

Tom Van den Mooter is an author at Cliniques Universitaires Saint-Luc specializing in oncology, medicine, and radiation oncology.

Top concepts

Publications per year

2017–2023

3

Publications

3

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).

Matt D. Galsky, Gianluca Del Conte, Silvia Foti et al. · Journal of Clinical Oncology · 2022 · 85 citations

, , +17

Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit

Wiebren Tjalma, Tom Van den Mooter, T.J.M. Mertens et al. · European Journal of Obstetrics & Gynecology and Reproductive Biology · 2017 · 46 citations

, , +7

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Laurence Buisseret, Delphine Loirat, Philippe Aftimos et al. · Nature Communications · 2023 · 23 citations · Full text

Rows per page

1–3 of 3